Forte Biosciences Shares Jump on Positive Vitiligo Study Results

Dow Jones

Jul 09

Shares of Forte Biosciences rose after the company said a placebo-controlled study in vitiligo showed meaningful improvement within about two months and that gains continued through six months, even after dosing ended.

Shares were recently up 38% at $28.40 in late Thursday morning trading. The stock has more than doubled over the past year.

Forte said its antibody, FB102, produced a 29.6% average improvement from baseline at week 24 versus placebo in the main analysis, with statistically significant gains observed by day 64 and continued improvement after dosing stopped. In patients with more extensive disease at the start, the average improvement was 43.2%, and more than half reached at least a 50% improvement by week 24.

The company said side effects were mild to moderate and compared favorably with placebo. Forte described FB102 as a monoclonal antibody that blocks CD122 to modulate IL-2- and IL-15-dependent T-cell activity while preserving regulatory T cells.

Write to Doc Louallen at Doc.Louallen@wsj.com

(END) Dow Jones Newswires

July 09, 2026 10:51 ET (14:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2650097892"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2650097892\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2650097892?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 22:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650097892","market":"sh","top_or_hot":-1,"title":"Forte Biosciences Shares Jump on Positive Vitiligo Study Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Forte Biosciences rose after the company said a placebo-controlled study in vitiligo showed meaningful improvement within about two months and that gains continued through six months, even after dosing ended. \n</p>\n<p>\n  Shares were recently up 38% at $28.40 in late Thursday morning trading. The stock has more than doubled over the past year. \n</p>\n<p>\n  Forte said its antibody, FB102, produced a 29.6% average improvement from baseline at week 24 versus placebo in the main analysis, with statistically significant gains observed by day 64 and continued improvement after dosing stopped. In patients with more extensive disease at the start, the average improvement was 43.2%, and more than half reached at least a 50% improvement by week 24. \n</p>\n<p>\n  The company said side effects were mild to moderate and compared favorably with placebo. Forte described FB102 as a monoclonal antibody that blocks CD122 to modulate IL-2- and IL-15-dependent T-cell activity while preserving regulatory T cells. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2026 10:51 ET (14:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences Shares Jump on Positive Vitiligo Study Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences Shares Jump on Positive Vitiligo Study Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-09 22:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Forte Biosciences rose after the company said a placebo-controlled study in vitiligo showed meaningful improvement within about two months and that gains continued through six months, even after dosing ended. \n</p>\n<p>\n  Shares were recently up 38% at $28.40 in late Thursday morning trading. The stock has more than doubled over the past year. \n</p>\n<p>\n  Forte said its antibody, FB102, produced a 29.6% average improvement from baseline at week 24 versus placebo in the main analysis, with statistically significant gains observed by day 64 and continued improvement after dosing stopped. In patients with more extensive disease at the start, the average improvement was 43.2%, and more than half reached at least a 50% improvement by week 24. \n</p>\n<p>\n  The company said side effects were mild to moderate and compared favorably with placebo. Forte described FB102 as a monoclonal antibody that blocks CD122 to modulate IL-2- and IL-15-dependent T-cell activity while preserving regulatory T cells. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2026 10:51 ET (14:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2650097892","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650097892","pubTimestamp":1783608660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Forte Biosciences rose after the company said a placebo-controlled study in vitiligo showed meaningful improvement within about two months and that gains continued through six months, even after dosing ended.Shares were recently up 38% at $28.40 in late Thursday morning trading. The stock has more than doubled over the past year.Forte said its antibody, FB102, produced a 29.6% average improvement from baseline at week 24 versus placebo in the main analysis, with statistically significant gains observed by day 64 and continued improvement after dosing stopped. In patients with more extensive disease at the start, the average improvement was 43.2%, and more than half reached at least a 50% improvement by week 24.The company said side effects were mild to moderate and compared favorably with placebo. Forte described FB102 as a monoclonal antibody that blocks CD122 to modulate IL-2- and IL-15-dependent T-cell activity while preserving regulatory T cells.Write to Doc Louallen at D","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","FBRX":"Forte BioSciences Inc"},"translate_title":"复地生物科学公司股价因白癜风研究结果积极而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBRX":0.9},"content_text":"Shares of Forte Biosciences rose after the company said a placebo-controlled study in vitiligo showed meaningful improvement within about two months and that gains continued through six months, even after dosing ended. \n\n\n  Shares were recently up 38% at $28.40 in late Thursday morning trading. The stock has more than doubled over the past year. \n\n\n  Forte said its antibody, FB102, produced a 29.6% average improvement from baseline at week 24 versus placebo in the main analysis, with statistically significant gains observed by day 64 and continued improvement after dosing stopped. In patients with more extensive disease at the start, the average improvement was 43.2%, and more than half reached at least a 50% improvement by week 24. \n\n\n  The company said side effects were mild to moderate and compared favorably with placebo. Forte described FB102 as a monoclonal antibody that blocks CD122 to modulate IL-2- and IL-15-dependent T-cell activity while preserving regulatory T cells. \n\n\n \n\n\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 09, 2026 10:51 ET (14:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}